{'fraction_non_alphanumeric': 0.042086001829826164, 'fraction_numerical': 0.04025617566331199, 'mean_word_length': 5.111731843575419, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Correlation between GIST positive CD117 with EGFR expression based on tumor size and mitotic index

Background: Gastrointestinal Stromal Tumors (GIST) are mesenchymal malignancies in GI tract. GIST resistant to imatinib therapy are widely reported. Epidermal Growth Factor Receptor (EGFR) plays a role in progressivity of malignancy. This study aimed at analyzing the expression of EGFR on GIST that leads to the probability of using Anti-EGFR as a substitutive therapy for Imatinib-resistance GIST. Methods: This study performed in Dr. Soetomo General Hospital in CD-117 positive GIST from 2009 to 2014. The number of the samples were 39, samples were measured using semi quantitative method, and analyzed using Spearman formula. Results: CD-117 positive GIST showed EGFR expression in 74.4% samples, Correlation between EGFR expression with the tumor size (p=0.129) and mitotic index (p=0.626). Conclusion: CD-117 positive GIST showed EGFR expression in 74.4% samples, though there was no significant correlation between EGFR expression with tumor size (p=0.129) and mitotic index (p=0.626).